Combination of (a) N- {5-[4-(4-methyl-piperazino-methyl)-benz oylamido]-2methylphenyl}-4-(3-pyridyl)-2-pyri midine-amine and (b) at least one hypusination inhibitor and the use thereof

Details for Australian Patent Application No. 2004298761 (hide)

Owner Novartis AG

Inventors Bruemmendorf, Tim H.; Kammer, Winfried; Balabanov, Stefan; Nordheim, Alfred; Hartmann, Ulrike

Agent Davies Collison Cave

Pub. Number AU-A-2004298761

PCT Pub. Number WO2005/058320

Priority 60/531,563 19.12.03 US

Filing date 17 December 2004

Wipo publication date 30 June 2005

International Classifications

A61K 31/44 (2006.01) - Non-condensed pyridines

A61K 31/505 (2006.01) - Pyrimidines

Event Publications

22 June 2006 PCT application entered the National Phase

  PCT publication WO2005/058320 Priority application(s): WO2005/058320

28 May 2009 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004298762-Device for changing the shape of the mitral annulus

2004298760-Use of sphingosine-1-phosphate (S1P) receptor agonists for the treatment of brain degenerative diseases